Loading fund overlap…
14 of 53 unique stocks in common · Jaccard: 26.4%
A weighted portfolio overlap of 31.19% indicates a moderate overlap (a meaningful shared core). This means that out of every ₹100 you invest across these two schemes, approximately ₹31.19 is allocated to the exact same companies at the same relative proportions. The schemes share 14 common holdings.
The largest overlapping asset in their portfolios is Mankind Pharma, which commands a weight of 4.49% in Back to Index and 3.77% in Tata India Pharma & Healthcare Fund. Holding both schemes increases your concentration in Mankind Pharma rather than expanding your diversification.
If the overlap is above 30%, it is typically because both schemes benchmark to the same index (e.g. Nifty 50 or Nifty LargeMidcap 250) or overlap in their top large-cap picks. To improve your portfolio's diversification, consider allocating one of these tranches to a category with lower structural correlation (such as a mid-cap, small-cap, or international equity fund).
| Stock | in Back | in Tata |
|---|---|---|
| Mankind PharmaPharmaceuticals & Biotechnology | 4.49% | 3.77% |
| Fortis HealthcareHealthcare Services | 8.50% | 3.41% |
| LupinPharmaceuticals & Biotechnology | 9.88% | 2.76% |
| Sai Life SciencesPharmaceuticals & Biotechnology | 2.60% | 2.73% |
| Alkem LaboratoriesPharmaceuticals & Biotechnology | 5.58% | 2.42% |
| Abbott IndiaPharmaceuticals & Biotechnology | 2.32% | 5.41% |
| JB Chemicals & PharmaceuticalsPharmaceuticals & Biotechnology | 2.95% | 2.24% |
| Ajanta PharmaPharmaceuticals & Biotechnology | 2.10% | 1.89% |
| Neuland LaboratoriesPharmaceuticals & Biotechnology | 2.28% | 1.89% |
| GlaxoSmithKline PharmaceuticalsPharmaceuticals & Biotechnology | 1.71% | 3.26% |
| Dr. Lal Path LabsHealthcare Services | 1.88% | 1.68% |
| Global HealthHealthcare Services | 1.67% | 2.20% |
| Syngene InternationalHealthcare Services | 1.57% | 2.65% |
| PfizerPharmaceuticals & Biotechnology | 1.26% | 1.63% |
Weighted overlap = Σ min(weight in fund A, weight in fund B) across shared stocks, from each fund's latest public monthly portfolio (as on May 2026). Equity holdings only, ISIN-verified. Not investment advice.